Ochre News

NEWS COVERAGE

Unlock the potential of complex human liver data

UK startups are built on immigrant talent, the UK will fail if it forgets this

Future of liver drugs – better AI or better data?

Ochre Bio: fully human, super speedy liver drug development

Exploring liver disease therapies 

Ochre Bio with CEO/Co-founder Jack O’Meara and liver expert Dr Scott Friedman, Mount Sinai

Revolutionising Liver Transplants: Can Phenotyping Drive Biotech Transformation in Healthcare?

Business of Biotech with Ochre Bio’s Quin Wills, M.D., PH.D

Ochre Bio CEO named on Forbes 30 Under 30 Europe

18 European techbio startups to watch — according to investors

The intersection between healthcare, technology, strategy and impact – Interview with Ochre Bio’s CEO and co-founder Jack O’Meara

AI and computational biology transforming chronic liver disease research 

‘I wanted to do something in health but I didn’t want to be a doctor’: Ochre Bio founder Jack O’Meara

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Oxford biotech raises funds to make RNA treatments for liver disease

RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease

A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round

Skydivers raise almost £10,000 for children at Helen & Douglas House

A New Era in European Life Sciences Investment

Chirps, chats and Clubhouses: First-time biotech founders turn to social media for advice, investors and recruitment

Lyfebulb and CSL Behring Announce the Finalists for the 2021 Transplant Innovation Challenge

‘Day job and a gay job’: LGBTQ+ leaders in biopharma want those who look, talk and love like them to be seen and counted

Biotech Startup Ochre Bio Lands Seed Financing to Combat Liver Diseases

Biotech looks to upset the preclinical model for liver drug development, and now it’s gearing up for the clinic

New hope for beating the hidden fatty liver epidemic, a silent killer

Entrepreneur First’s Latest European Cohort Revealed, With Plenty Of Biotech Startups On Show

All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits

Join our Mailing List